Estimating the costs of intensity-modulated and 3-dimensional conformal radiotherapy in Ontario

Current Oncology

Volumn 23, Issue 3, 2016, Pages e228-e238

  Yong, J H E ^a,b,c   McGowan, T ^d,e,f   Redmond Misner, R ^a,b,c   Beca, J ^a,b,c   Warde, P ^b,d,g   Gutierrez, E ^b   Hoch, Jeffrey S ^a,b,c,h  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b CANCER CARE ONTARIO   (Canada)

^c Canadian Centre for Applied Research in Cancer Control (ARCC)   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e The Cancer Centre Bahamas   (Bahamas)

^f The Cancer Centre Eastern Caribbean   (Antigua and Barbuda)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast neoplasms; Cost analyses; Costs; Head andneck neoplasms; Intensity modulated radiotherapy; Prostate neoplasms; Radiotherapy

Indexed keywords

3 DIMENSIONAL CONFORMAL RADIOTHERAPY; ARTICLE; BREAST CANCER; CANADA; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DOSIMETRY; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; NEOPLASM; PROSTATE CANCER; SENSITIVITY ANALYSIS;

EID: 84974593842     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.23.2998     Document Type: Article

References (33)

1. Cancer Quality Council of Ontario (cqco). Radiation Therapy Evidence-based Series [Web page]. Toronto, ON: cqco; 2010. [Available at: https://www.cancercare.on.ca/cms/One.aspx?portalId=289784&pageId=10445; cited 18 December 2015]
2. Al-Mamgani A, Heemsbergen D, Peeters T, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009;73:685–91.
3. Braam PM, Terchaard CH, Roesink JM, Raaijmakers CP. Intensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:975–80.
4. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007;25:4873–9.
5. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124–9.
6. Nutting CM, Morden JP, Harrington KJ, et al. on behalf of the parsport trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (parsport): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011;12:127–36.
7. Amin NP, Sher DJ, Konski AA. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013. Appl Health Econ Health Policy 2014;12:391–408.
8. Chen A, Kim J, Boucher K, et al. Toxicity and cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for postoperative treatment of gynecologic cancers. Gynecol Oncol 2015;136:521–8.
9. Hodges C, Beg MS, Das P, Meyer J. Cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for anal cancer. Int J Radiat Oncol Biol Phys 2014;89:773–83.
10. Hummel SR, Stevenson MD, Simpson EL, Staffurth J. A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer. Clin Oncol (R Coll Radiol) 2012;24:e159–67.
11. Kohler E, Sheets NC, Wheeler SB, Nutting C, Hall E, Chera BA. Two-year and lifetime cost-effectiveness of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2013;87:683–9.
12. Sheets NC, Wheeler SB, Kohler RE, Fried DV, Brown PM, Chera BS. Costs of care in a matched pair comparison of intensitymodulated radiation therapy (imrt) versus conventional radiation therapy (crt) for the treatment of head and neck cancer. Am J Clin Oncol 2014;37:539–44.
13. Carter HE, Martin A, Schofield D, et al. A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (imrt) compared to three dimensional conformal radiation therapy (3dcrt) in patients receiving radiotherapy to the prostate bed. Radiother Oncol 2014;112:187–193.
14. Poon I, Pintilie M, Potvin M, McGowan T. The changing costs of radiation treatment for early prostate cancer in Ontario: a comparison between conventional and conformal external beam radiotherapy. Can J Urol 2004;11:2125–32.
15. Lievens Y, van den Bogaert W, Kesteloot K. Activity-based costing: a practical model for cost calculation in radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:522–35.
16. Ploquin NP, Dunscombe PB. The cost of radiation therapy. Radiother Oncol 2008;86:217–23.
17. Lievens Y, Slotman BJ. Radiotherapy cost-calculation and its impact on capacity planning. Expert Rev Pharmacoecon Outcomes Res 2003;3:497–507.
18. Canadian Agency for Drugs and Technologies in Health (cadth). Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd ed. Ottawa, ON: cadth; 2006. [Available online at: https://www.cadth.ca/media/pdf/186_ EconomicGuidelines_e.pdf; cited 18 December 2015]
19. Ontario Ministry of Health and Long-Term Care (mohltc). Ontario Health Insurance (OHIP) Schedule of Benefits for Physician Services. Toronto, ON: mohltc; 2009.
20. Drummond MF, Sculpher MJ, Torrance G, O’Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford, UK: Oxford University Press; 2005.
21. International Atomic Energy Agency (iaea). Record and Verify Systems for Radiation Treatment of Cancer: Acceptance Testing, Commissioning and Quality Control. Vienna, Austria: iaea; 2013.
22. Wodinsky HB, Jenkin RD. The cost of radiation treatment at an Ontario regional cancer centre. CMAJ 1987;137:906–9.
23. Warde P, Murphy T. Measuring the cost of palliative radiotherapy. Can J Oncol 1996;6(suppl 1):90–4.
24. Fogarty GB, Ng D, Liu G, Haydu LE, Bhandari N. Volumetric modulated arc therapy is superior to conventional intensity modulated radiotherapy—a comparison among prostate cancer patients treated in an Australian centre. Radiat Oncol 2011;6:108.
25. Clark CH, Mubata CD, Meehan CA, et al. imrt clinical implementation: prostate and pelvic node irradiation using Helios and a 120-leaf multileaf collimator. J Appl Clin Med Phys 2002;3:273–84.
26. Miles EA, Clark CH, Urbano MT, et al. The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiother Oncol 2005;77:241–6.
27. Van de Werf E, Lievens Y, Verstraete J, Pauwels K, van den Bogaert W. Time and motion study of radiotherapy delivery: economic burden of increased quality assurance and imrt. Radiother Oncol 2009;93:137–40.
28. Williams MV, Hoole AC, Dean JC, et al. imrt can be faster to deliver than conformal radiotherapy. Radiother Oncol 2010;95:257–8.
29. Van de Werf E, Verstaete J, Lievens Y. The cost of radiotherapy in a decade of technology evolution. Radiother Oncol 2012;102:148–53.
30. Thomas SJ, Vinall A, Poynter A, Routsis D. A multicentre timing study of intensity-modulated radiotherapy planning and delivery. Clin Oncol (R Coll Radiol) 2010;22:658–65.
31. Yong JH, Beca J, McGowan T, Bremner KE, Warde P, Hoch JS. Cost-effectiveness of intensity-modulated radiotherapy in prostate cancer. Clin Oncol (R Coll Radiol) 2012;23:521–31.
32. Yong J, Beca J, O’Sullivan B, et al. Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer. Clin Oncol (R Coll Radiol) 2012;24:532–8.
33. Dunscombe P, Roberts G, Walker J. The cost of radiotherapy as a function of facility size and hours of operation. Br J Radiol 1999;72:598–603.